Gilead Analysis Shows Remdesivir Reduced Coronavirus Death R
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Gilead Sciences announced new findings Friday ( 10 July) that its antiviral drug remdesivir reduced the risk of death for severely sick coronavirus patients by 62% compared with standard care alone, saying more research is needed.

The company said its analysis also found that remdesivir treatment was associated with “significantly improved clinical recovery.”

In the latest analysis, Gilead said it analyzed data from 312 patients treated in its late-stage study and a separate real-world retrospective cohort of 818 patients with similar characteristics and disease severity.

Gilead's late-stage study evaluated the safety and efficacy of five-day and 10-day dosing durations of remdesivir in hospitalized patients. The study did not have a placebo comparison.

The findings show that 7.6% of patients treated with remdesivir died compared with 12.5% of patients in the analysis who did not receive remdesivir treatment.

The analysis also found that 74.4% of patients who received treatment with remdesivir recovered by day 14 compared with 59% of patients who received standard care alone.

The U.S. government trial in April showed that patients given remdesivir recovered 31% faster than those given a placebo.

Source: https://www.cnbc.com/2020/07/10/gilead-says-remdesivir-coronavirus-treatment-reduces-risk-of-death.html
Dr. T●●●●z H●●●●●●i and 5 others like this4 shares
Like
Comment
Share